ЧÀÍÈÈÏß
×ðÖØ¿Æѧ ¾´Î·ÖÆ¶È ×·ÇóЧÂÊ ¹Ø°®ÉúÃü
ѧÊõ¶¯Ì¬
¡¾HDSÊÖÒÕ×îÐÂÏ£Íû¡¿¡¶Frontiers in Oncology¡·±¨µ¼ÀûÀ´w66HDS¾«×¼ÓÃÒ©µä·¶°¸Àý2Àý
Ðû²¼Ê±¼ä£º
2021-09-01
½üÆÚ£¬£¬ £¬£¬£¬ÖйúÒ½¿Æ´óѧÁ¥ÊôµÚһҽԺѪҺÄÚ¿ÆÔÚ Frontiers in Oncology ÆÚ¿¯Éϱ¨µ¼ÁË2ÀýÌØÊⲡÀý£ºÒ»ÀýÓÐÊýµÄ³ÉÈËB-ALLºÏ²¢TCF3-ZNF384»ùÒòÖØÅŲ¡Àý£¬£¬ £¬£¬£¬ºÍÒ»Àý°éSET-CAN/NUP214ÈںϵĶùͯT-ALL²¡Àý¡£¡£¡£¡£¡£¡£¡£
2¸ö²¡Àýͨ¹ýHDSÌåÍâÒ©Ãô¼ì²âÊÖÒÕ̽Ë÷¸öÌ廯ÖÎÁÆÈ¡µÃÁËÍêÈ«»º½â£¬£¬ £¬£¬£¬¸øÓÐÊýÈںϻùÒòÅä¾°µÄALLÖÎÁÆÌṩÁËеÄ˼Ð÷ºÍģʽ£¬£¬ £¬£¬£¬ÒýÆðÁËÆÕ±é¹Ø×¢¡£¡£¡£¡£¡£¡£¡£
°¸ÀýÒ»£º³ÉÈËB-ALLºÏ²¢TCF3-ZNF384ÓÐÊý»ùÒòÖØÅÅ
»¼Õߣº41Ë꣬£¬ £¬£¬£¬ÄÐÐÔ£¬£¬ £¬£¬£¬2020Äê11ÔÂÈ·ÕïΪB-ALL£¬£¬ £¬£¬£¬ºÏ²¢TCF3-ZNF384ÓÐÊý»ùÒòÖØÅÅ£¬£¬ £¬£¬£¬»¼ÕßÔÚÒ»¸öÀο¿»¯ÁÆÖÜÆÚºó¸´·¢¡£¡£¡£¡£¡£¡£¡£
ͼƬȪԴ£ºFrontiers in Oncology July 2021 | Volume 11
ÒªÁ죺ȡÆä¹ÇËèÑù±¾¾ÙÐÐÌåÍâ°×Ѫ²¡Ï¸°û×÷Óý£¬£¬ £¬£¬£¬¶Ô156ÖÖϸ°û¶¾ÐÔÒ©Îï¡¢°ÐÏòÖÎÁÆÒ©Îï¡¢ÁªºÏ»¯ÁÆÒ©ÎïµÈ¾ÙÐÐÃô¸ÐÐÔɸѡ£¬£¬ £¬£¬£¬ÒÔÆÚÑ°ÕÒ¿ÉÄܵÄÖÎÁƼƻ®¡£¡£¡£¡£¡£¡£¡£
Ч¹û£º¼ì²â·¢Ã÷»¼Õ߸´·¢°×Ѫ²¡Ï¸°û¶Ô¼±ÐÔËèϸ°û°×Ѫ²¡£¡£¡£¡£¡£¡£¡£¨AML£©ºÍ¼±ÐÔÁÜ°Íϸ°û°×Ѫ²¡£¡£¡£¡£¡£¡£¡£¨ALL£©µÄÁªºÏ»¯ÁƼƻ®¼°¶àÖÖ°ÐÏòÒ©Îï¾ùÏÔʾÖжÈÃô¸Ð¡£¡£¡£¡£¡£¡£¡£ÆäÖУ¬£¬ £¬£¬£¬hyper-CVAD£¨B£©¼Æ»®ÏÔʾ³öÓë¶à¸ö°ÐÏò»¯ºÏÎïµÄÐͬЧӦ£¬£¬ £¬£¬£¬²¢ÇÒ¾ßÓнϸߵÄÖ×Áöϸ°ûɱÉËÒÖÖÆÂÊ¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»¼ÕßÑ¡Ôñ¸ßCVAD£¨B£©¼Æ»®ÓëË÷À·ÇÄáÁªºÏ£¬£¬ £¬£¬£¬»ñµÃÍêÈ«»º½â£¨CR£©£¬£¬ £¬£¬£¬È»ºóÓëËèϵ¶¨Ïò¸ßÈý¼âɼõ¥¼î+°¢ÌÇ°ûÜÕ+ÈáºìùËØ£¨HAD£©¼Æ»®ºÏ²¢£¬£¬ £¬£¬£¬»ñµÃ·Ö×ÓCR¡£¡£¡£¡£¡£¡£¡£
ר¼ÒµãÆÀ
ÎÞÂÛÃâÒß±íÐÍÔõÑù£¬£¬ £¬£¬£¬TCF3-ZNF384°×Ѫ²¡¿ÉÄÜÊÇÒ»ÖÖÆæÒìµÄ°×Ѫ²¡ÑÇÐÍ¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£Ë¼Á¿µ½ÆµÈÔµÄÆ×ϵת»»ÒÔ¼°¶ÔALLºÍAMLµ¼Ïò¼Æ»®µÄÃô¸ÐÐÔ£¬£¬ £¬£¬£¬½ÓÄÉÁÜϵ¡¢ËèϵºÍÔìѪ¸Éϸ°ûµÄÕûºÏÕ½ÂÔÓпÉÄÜΪTCF3-ZNF384ÐͳÉÈË°×Ѫ²¡ÕÒµ½³ö·£¬£¬ £¬£¬£¬Ð¡·Ö×Ó°ÐÏòÒ©ÎïÌåÏÖ³öÒ»¶¨µÄDZÔÚ¼ÛÖµ£¬£¬ £¬£¬£¬ÖµµÃ½øÒ»²½Ì½ÌÖÑо¿¡£¡£¡£¡£¡£¡£¡£
°¸Àý¶þ£º°éSET-CAN/NUP214ÈںϵĶùͯT-ALL
»¼Õߣº15Ë꣬£¬ £¬£¬£¬Å®º¢£¬£¬ £¬£¬£¬2019Äê10ÔÂÈ·ÕïΪT-ALL£¬£¬ £¬£¬£¬°éÓÐSET-CAN/NUP214Èںϣ¬£¬ £¬£¬£¬¶ÔͨÀýVICLP»¯ÁÆÌåÏÖ³öÔçÆÚÄÍÒ©ÐÔ£¨µÚ15Ì죬£¬ £¬£¬£¬79.2%µÄBLAST£©£¬£¬ £¬£¬£¬Ö»¹ÜÔÚµÚ28ÌìÓÕµ¼»¯Áƺó£¨18.85%µÄBLAST£©£¬£¬ £¬£¬£¬°×Ѫ²¡¼ç¸ºÏÔÖø¼õÇᣬ£¬ £¬£¬£¬µ«ÔÚµÚ¶þ¸öÁƳÌʹÓôó¼ÁÁ¿¼×°±µûßʺ;ÛÒÒ¶þ´¼ÌìÃŶ¬°±ËáºóÈÔδµÖ´ïÍêÈ«»º½â¡£¡£¡£¡£¡£¡£¡£
ͼƬȪԴ£ºFrontiers in Oncology March 2021 | Volume 11
ÒªÁ죺ȡÆä¹ÇËèÑù±¾¾ÙÐÐÌåÍâ°×Ѫ²¡Ï¸°û×÷Óý£¬£¬ £¬£¬£¬¶Ô165ÖÖϸ°û¶¾ÐÔÒ©Îï¡¢°ÐÏòÖÎÁÆÒ©Îï¡¢ÁªºÏ»¯ÁÆÒ©ÎïµÈ¾ÙÐÐÌåÍâÒ©ÎïÃô¸ÐÐÔɸѡ¡£¡£¡£¡£¡£¡£¡£
Ч¹û£ºÁîÈ˾ªÑȵÄÊÇ£¬£¬ £¬£¬£¬AMLÑù¼Æ»®DAE¼Æ»®£¨ÈáºìùËØ+°¢ÌÇ°ûÜÕ+×ãÒ¶ÒÒß°£©ºÍ¿¨·Ç×ôÃ×µÄÌåÍâÒÖÖÆÂÊ×î¸ß¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»¼Õß½ÓÊÜDAE¼Æ»®»¯ÁÆ£¬£¬ £¬£¬£¬×îÖÕÍêÈ«»º½â²¢½ÓÊÜÒì»ùÒòÔìѪ¸Éϸ°ûÒÆÖ²£¨allo-HSCT£©¡£¡£¡£¡£¡£¡£¡£
ר¼ÒµãÆÀ
SET-CAN/NUP214ÈںϵÄT-ALL»¼Õßͨ³£¶Ô»¯ÁÆÌåÏÖ³öÔçÆÚÄÍÒ©ÐÔ£¬£¬ £¬£¬£¬µ«ËûÃÇÓÐÑÓ³Ù·´Ó¦£¬£¬ £¬£¬£¬²¢ÇÒCRÂÊûÓнµµÍ£¬£¬ £¬£¬£¬Òò´Ë£¬£¬ £¬£¬£¬½¨ÒéÓÕµ¼ÖÎÁƽÓÄÉ28ÌìÁƳ̵Ļ¯ÁƼƻ®£¬£¬ £¬£¬£¬ÈçGRAALL 2003Äê»ò2005ÄêʹÓõĻ¯ÁƼƻ®¡£¡£¡£¡£¡£¡£¡£
¶ÔÄÑÖÎÐÍT-ALL»¼¶ù£¬£¬ £¬£¬£¬AMLÑùÖÎÁÆÈçDAE»òCLAGÁªºÏÌ춬õ£°·Ã¸¿ÉÄÜÊÇÓÐÒæµÄ¡£¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬ £¬£¬£¬¿¨·Ç×ôÃ׿ÉÄÜÊÇÒ»ÖÖÓÐÓõÄÖÎÁÆÒ©Î£¬ £¬£¬£¬ÖµµÃ½øÒ»²½Ñо¿¡£¡£¡£¡£¡£¡£¡£ÎÒÃÇÏàÐÅ£¬£¬ £¬£¬£¬Í¨¹ýÒ©ÃôÊÖÒÕµÄÖ¸µ¼¾ÙÐÐÊʵ±µÄÖÎÁÆ£¬£¬ £¬£¬£¬SET-CAN/NUP214Èںϻ¼ÕßµÄÔ¤ºó¿ÉÒÔ´ó´ó¸ÄÉÆ£¬£¬ £¬£¬£¬ÖÁÉÙ²»±ÈÆäËûT-ALL»¼Õ߲¡£¡£¡£¡£¡£¡£
ÏàÖúµ¥Î»ÏÈÈÝ
¿ÆÊÒ¼ò½é£ºÖйúÒ½¿Æ´óѧÁ¥ÊôµÚһҽԺѪҺÄڿƽ¨ÉèÓÚ1960Ä꣬£¬ £¬£¬£¬ÊǶ«±±×ÅÃûµÄѪҺ²¡ÖÎÁÆÖÐÐÄ¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿ÆÊÒÓµÓÐͨËײ¡´²100ÕÅ£¬£¬ £¬£¬£¬²ãÁ÷²¡´²4ÕÅ£¬£¬ £¬£¬£¬ÑªÒº²¡ÊµÑéÊÒ1¸ö£¬£¬ £¬£¬£¬ÄêÃÅÕïÊÕÖλ¼Õß35000ÓàÈ˴Σ¬£¬ £¬£¬£¬Ä겡·¿ÊÕÖλ¼Õß½ü3000È˴Σ¬£¬ £¬£¬£¬ÏÖÓÐÒ½Éú21Ãû¡£¡£¡£¡£¡£¡£¡£
ÊÖÒÕÖ§³Ö£ºÀûÀ´w66¹«Ë¾ÒÀÍÐÖйú¿ÆѧԺÁõÇàËÉÑо¿ÍŶӣ¬£¬ £¬£¬£¬Ê¹ÓÃ×ÔÖ÷¿ª·¢µÄÔ´úϸ°û¿ÉÔÙÍâÐÐÒÕ¿ª·¢ÁËÁýÕÖÈ«°©ÖÖµÄHDSÒ©Ãô¼ì²âϵͳ£¨High-throuphput Drug Sensitivity Analysis Strategy£©£¬£¬ £¬£¬£¬¿ÉÔÚ7-10ÌìÄÚʹÓÃÖ×Áö»¼ÕßÉÙÁ¿Ö×ÁöÑù±¾¾ÙÐÐÉÏ°ÙÖÖÒ©ÎïµÄÃô¸ÐÐÔ¼ì²â£¬£¬ £¬£¬£¬×ÊÖúÖ×Áö»¼Õß½â¾ö“³Ôʲôҩ¡¢ÄÍÒ©¡¢ÎÞÒ©¿É³Ô”µÄÄÑÌ⣬£¬ £¬£¬£¬¾ßÓÐÖÜÆڶ̡¢ÀÖ³ÉÂʸߡ¢¼ì²âÒ©Îï¶à¡¢ÁÙ´²Ò»ÖÂÐԸߵÈÌص㣬£¬ £¬£¬£¬ÎªÖ×ÁöÒ½ÉúµÄ¸öÌ廯ÖÎÁƾöÒéÌṩ֤¾ÝÖ§³Ö¡£¡£¡£¡£¡£¡£¡£
С½á
Á½¸ö²¡Àý¶¼ÌáÐÑÔÚÓÐÊýÄÑÖÎÐÍ°×Ѫ²¡µÄÖÎÁÆÖУ¬£¬ £¬£¬£¬¿É½ÓÄÉËèϵ¼Æ»®½â¾öÁÜϵÄÑÌâµÄ“ÀÏÒ©ÐÂÓÔÁ¢Òì˼Ð÷£¬£¬ £¬£¬£¬¶øÌåÍâÒ©Ãô¿ÉÒÔÈÃÕâÑùµÄÑ¡ÔñÓоݿÉÒÀ£¬£¬ £¬£¬£¬Á½Àýcase reportΪҩÃôɸ²éÖ¸µ¼ÏµĸöÌ廯׼ȷÖÎÁÆÌṩÁËÓÅÒìµÄ²Î¿¼Ä£Ê½¡£¡£¡£¡£¡£¡£¡£
ÀûÀ´w66¹«ÖÚºÅ
Á¢ÒìÒ©ÎïÆÀ¼Û
ÖпÆÒ½ÂöС³ÌÐò
µç»°£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
꿅᣼www.precedo.cn
µØµã£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°
Copyright © 2021 ÀûÀ´w66 °æȨËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ºÏ·Ê